March 2018

It was a pleasant surprise to see not one, but two recent commentaries on the subject of biosimilars in prestigious publications such as the New England Journal of Medicine (NEJM) and the Journal of Clinical Oncology (JCO). More

“First, do no harm,” the Hippocratic Oath says. In today’s environmentally complex world, that becomes more of a challenge because people and the planet may unintentionally be harmed by the very products and processes meant to heal. More

Lowering costs in the health care supply chain begins at the negotiating table. Multiple vendors are considered and clinicians are often deeply involved in product selection. The volume commitment is factored in, and the price is set. More

Three decades ago, health care was largely a service industry, structured around individual physician practices: doctors treated patients, hospitals provided supporting resources, and insurers or the government (through Medicare and Medicaid) paid costs plus a small margin. More